Stock Analiz

INCY vs MEDP stock comparison

Incyte vs. Medpace · data as of November 13, 2026

Incyte (INCY) has a market value of about $24.7B, Medpace (MEDP) about $18.3B. Over their latest twelve months Incyte had revenue of $6.0B and Medpace $2.8B.

On our five checks Medpace scores higher: 3.2 out of 5 (average) against 2.8 (average).

By area, the stronger company is Medpace on value; Medpace on track record; Incyte on financial health.

Medpace is cheaper on earnings (P/E 36.3 vs. 61.7).

Incyte leads on 6 of the compared lines and Medpace on 12.

Side by side

INCYMEDP
Size and price
Market cap$24.7B$18.3B
Share price$120.97$653.94
Score
Overall score (of 5)2.83.2
Value01
Future growth44
Track record35
Financial health54
Shareholder returns22
Valuation
P/E (TTM)61.736.3
Forward P/E15.133.6
Price / free cash flow36.327.4
Price / sales4.16.4
EV / EBITDA29.527.9
PEG—1.14
DCF value vs. price−48%−32%
Business
Revenue$6.0B$2.8B
Net income$403M$518M
Free cash flow$680M$668M
Net margin6.7%18.2%
Gross margin (5-yr avg.)93.5%—
ROIC (5-yr avg.)10.6%41.9%
Growth
Revenue growth (1 yr)21.2%20.0%
Revenue growth (5 yrs, per year)14.0%22.3%
EPS growth (5 yrs, per year)—31.8%
Balance sheet and payouts
Net cash (cash minus debt)——
Dividend yieldNoneNone
Shareholder yield0.0%5.0%
Analysts
Upside to average target+9%−0%
Consensus ratingBuynone

Highlighted = the better figure on that line. Revenue, net income and free cash flow: INCY TTM to September 30, 2026, MEDP TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Incyte or Medpace?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Medpace scores 3.2 out of 5 and Incyte 2.8; the table shows where each one is stronger.

Is Incyte cheaper than Medpace?

On trailing earnings, Medpace trades at a P/E of 36.3 and Incyte at 61.7, so Medpace is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Incyte or Medpace?

Over five years Medpace grew revenue about 22.3% a year and Incyte about 14.0% a year.

Full Incyte analysis → Full Medpace analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.